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Intracranial pressure (ICP) monitoring is one of the mainstays in the treatment of severe 2	
traumatic brain injury (TBI), but different approaches to monitoring exist. The aim of this 3	
systematic review and meta-analysis is to compare the effectiveness and complication rate of 4	
ventricular drainage (VD) versus intracranial parenchymal (IP) catheters to monitor and treat 5	
raised ICP in patients with TBI. 6	
Pubmed, EMBASE, Web of Science, Google Scholar and the Cochrane Database were 7	
searched for articles comparing ICP monitoring-based management with VDs and monitoring 8	
with IP monitors until March 2018. Study selection, data extraction and quality assessment 9	
were performed independently by two authors. Outcomes assessed were mortality, functional 10	
outcome, need for decompressive craniectomy, length of stay, overall complications, such as 11	
infections, and hemorrhage. Pooled effect estimates were calculated with random effects 12	
models and expressed as relative risk (RR) for dichotomous outcomes and mean difference 13	
(MD) for ordinal outcomes, with corresponding 95% confidence intervals (CI). 14	
Six studies were included: 1 randomized controlled trial and 5 observational cohort studies.  15	
Three studies reported mortality, functional outcome and the need for a surgical 16	
decompression, three only reported complications. Quality of the studies was rated as poor, 17	
with critical or serious risk of bias. The pooled analysis did not show a statistically significant 18	
difference in mortality (RR=0.90, 95% CI=0.60 to 1.36, p=0.41) or functional outcome 19	
(MD=0.23, 95% CI=0.67 to 1.13, p=0.61). The complication rate of VDs was higher 20	
(RR=2.56, 95% CI=1.17 to 5.61, p= 0.02) and consisted mainly of infectious complications, 21	
i.e. meningitis. 22	
VDs caused more complications, particularly more infections but there was no difference in 23	
terms of mortality or functional outcome between the two monitoring modalities. However, 24	
the studies had a high risk of bias. A need exists for high quality comparisons of VDs versus 25	
IP monitor-based management strategies on patient outcomes. 26	
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Intracranial pressure (ICP) monitoring is one of the mainstays of current severe traumatic 3	
brain injury (TBI) treatment at the ICU and guidelines recommend using ICP monitoring in 4	
order to reduce mortality.1  5	
There is a wide range of intracranial pressure sensors. Two types are most commonly used: 6	
Ventricular drainage (VD) and intraparenchymal catheters. The IP monitor catheters require a 7	
small opening in the skull and their small diameters cause little damage to the brain 8	
parenchyma. They have a low risk of infection and other complications, such as intracerebral 9	
hemorrhage.2 The insertion of a ventricular catheter, usually into the frontal horn of the right 10	
lateral ventricle, requires a relatively larger opening and is thought to cause more damage to 11	
brain tissue than the insertion of a smaller parenchymal sensor.3 VDs fulfill two objectives: 12	
besides monitoring, they permit drainage of CSF, thereby acting as an ICP-lowering 13	
intervention. However, this is accomplished at the expense of an increased risk of infections 14	
and complications.2 15	
Not much is known about the superiority of one method over the other in terms of patient 16	
outcomes. In the second Brain Trauma Foundation Guidelines edition of 2000, in which this 17	
topic was addressed, no clear recommendation was made and in subsequent editions the topic 18	
was no longer addressed due to lack of evidence.4 However, recently, a randomized controlled 19	
trial (RCT) was conducted, the first of its kind, that suggested the superiority of VDs over IP 20	
monitors on patient outcomes. Next to this single RCT, several observational studies have 21	
been published. 22	
The aim of this study was to review the available evidence on the effectiveness and 23	
complication rate of VD versus IP-monitor-guided treatment of raised ICP in patients with 24	
TBI. 25	
 26	
Materials and methods 27	
A protocol has been published on Prospero.5 28	
Search strategy 29	
Searches were not restricted by date, language or publication status. In collaboration with an 30	
information specialist from the Erasmus MC library we developed a search strategy 31	
(Appendix 1). We performed the search in MEDLINE, EMBASE, ISI Web of Science, 32	
Pubmed and Google Scholar, from the first publicly accessible date of a particular database 33	
until March 1st, 2018. Ongoing studies were searched on clinicaltrials.gov. Grey literature 34	
was screened using Google Scholar and ISI Web of Science. Reference lists of all relevant 35	
trials were hand searched and experts in the field that had previously published on this matter 36	
were contacted for unpublished literature on this topic. 37	
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Ethical approval and consent 1	
This study did not require ethical approval. 2	
Inclusion criteria and study selection  3	
Given the expected scarcity of available literature on the topic, we included – next to RCTs - 4	
prospective and retrospective observational studies that described a direct comparison 5	
between patients with VDs and patients with IP monitoring and that reported either mortality, 6	
functional outcomes or complications. Inclusion criteria were: (1) mainly adult population, (2) 7	
severe or moderate TBI on admission defined as a Glasgow coma score (GCS) <=12 and (3) 8	
closed head injury 9	
Exclusion criteria were (1) penetrating or blast TBI, (2) studies with a predominantly 10	
paediatric population, (3) studies without VD and IP comparisons and (4) studies on external 11	
lumbar drainage 12	
For studies with mixed populations, including mixed ages (i.e. adults and children) and mixed 13	
injury types (i.e. TBI and stroke) we included studies in which the results for our population 14	
of interest were presented separately, or in which at least 85% of the participants represented 15	
our population of interest.  16	
Considering mixed injury types, one exception was made in the case of the secondary 17	
outcomes, i.e. infections, haemorrhage and catheter malfunctions. Since we did not expect any 18	
differences between mixed injury types (i.e. ischaemic stroke and severe TBI) in terms of 19	
complications when either device was used.  We therefore chose to pool all studies that 20	
compared complications in patients with an VD and those with an IP monitor in mixed injury 21	
types, even if the population represented < 85% severe TBI. 22	
The first phase involved screening the titles and abstracts (Appendix 3). Studies unrelated to 23	
the topics of VDs versus IP monitoring or TBI were excluded. In the second phase the 24	
remaining abstracts were screened for the inclusion and exclusion criteria.  25	
In the final sifting phase, the full text of the remaining studies was reviewed. Conflicts were 26	
resolved by discussion until a final decision was reached.  27	
 28	
Data extraction and risk of bias assessment 29	
Each study was assessed by  two investigators (VV, IH) and the data was extracted in a matrix 30	
consisting of trial details, such as: trial name and date, trial design, author contact 31	
information, inclusion and exclusion criteria, adherence to a published protocol,  number of 32	
patients, duration of intervention, mean age of patients, mean GCS, percentage of severe TBI, 33	
male to female ratio, whether the groups were comparable or not and the effect size and 34	
confidence intervals for the primary and secondary outcomes individually (Appendix 2). 35	
Finally, potential sources of bias and sources of funding were noted. 36	
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Quality assessment was performed by two authors independently (VV and JH). For the RCTs 1	
we used the Cochrane Collaboration’s Risk of Bias Assessment Tool6 (assessing the risk of 2	
bias as high/low or unknown for each domain) tool and for observational trials the ROBINS-I 3	
Cochrane tool7 (assessing the studies as low/moderate/serious or critical risk of bias for each 4	
domain and overall) (Appendix 4).  5	
 6	
Outcomes 7	
The primary outcomes were mortality and functional outcome at 6 months or final follow-up 8	
if earlier, defined by the Glasgow Outcome Scale/Extended (GOS/E). 9	
The secondary outcomes examined were: the need for decompressive craniectomy during ICU 10	
stay; the hospital and Intensive Care Unit (ICU) Lengths Of Stay (LOS); monitoring duration; 11	
device failure at any time point; all complications; infections, however defined in the paper; 12	
intracranial haemorrhage; and the number of episodes of refractory intracranial hypertension 13	
(RICH), defined as uncontrollable intracranial hypertension by conventional means requiring 14	
an increase in therapy intensity, either medical or surgical.   15	
We anticipated that all outcome data will be dichotomous. As such, for each study, we have 16	
extracted the number of participants receiving each device and the number of events (i.e. n/N) 17	
or the GOS mean differences.  18	





The relative risk (RR) and corresponding 95% Confidence Interval (CI) were extracted for 24	
mortality, need for decompressive craniectomy, overall complications (specifically for device 25	
failure, infection and haemorrhage), when available and otherwise calculated.  26	
The pooled RR and corresponding 95% CI was then determined using the Mantel-Haenszel 27	
approach, and its significance as the true effect estimate was assessed against the null 28	
hypothesis RR overall=1 using the z test. Statistical evidence for heterogeneity between 29	
studies was assessed using the Q-test and the I2 index estimated the between-study variability. 30	
We used the random effects model for all analyses, as considerable heterogeneity may exist 31	
despite the absence of statistical evidence of this, especially in studies with small sample 32	
sizes. 33	
For the outcomes reported as mean difference (MD) ± standard deviation (SD), we used the 34	
inverse variance method to obtain the pooled MD. In this case we also used the Q-test and  I2 35	
index to estimate statistical heterogeneity between studies. The outcomes were ICU and 36	
hospital LOS, mean monitoring duration and mean GOS for each group.   37	
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1208 studies underwent abstract screening. Among these, 37 were screened full text 5	
(Appendix 3). Six studies were included and characteristics of patients extracted (Appendix 2) 6	
with 3968 enrolled patients in total (minimum 122 patients8, maximum 2562 patients9). One 7	
of these was an RCT, the rest were retrospective observational cohorts. Three studies included 8	
data on mortality, functional outcome, LOS and surgical decompression, the other three 9	
reported only complications.  10	
Primary outcome 11	
Three studies with 3013 patients reported mortality rates.8-10 When the results were 12	
aggregated, mortality was not different between VD and IP monitors (RR=0.90, 95% CI=0.60 13	
to 1.36, p=0.63). There was substantial heterogeneity (I2= 76%, p value of the Q test=0.01) 14	
(Figure 1a).  15	
In the analysis of studies reporting functional outcome at the end of follow-up, 2 papers 16	
involving 451 patients described functional outcome data using the mean GOS difference.8, 10 17	
When the results were aggregated, mean GOS was not different between the two interventions 18	
(Mean Difference (MD) =0.23, 95% CI=-0.67 to 1.13, p=0.61). Heterogeneity was high (Q 19	
test p=0.003, I2=89%) (Figure 1b). 20	
 We contacted the authors of the Kasotakis et al study10 in order to obtain the absolute 21	
numbers of the functional outcome, but the data on these outcomes were not available 22	
anymore. 23	
Aiolfi et al9 only described the absolute numbers for patients functionally independent at 24	
discharge. For the 2562 patients described, there was no difference regarding this number 25	
between the two groups patients at discharge (RR= 0.97, 95% CI= 0.83 to 1.13). 26	
Secondary outcomes 27	
Three studies including 3968 patients examined the risk of needing a surgical decompression 28	
in both groups.8-10 There was no difference between the groups (RR= 0.79, 95% CI= 0.56 to 29	
1.10, p=0.16). Heterogeneity was large (Q-test p=0.005; I2=81%) (Figure 2a) . 30	
The mean LOS in the hospital8-10 did not differ between groups with no heterogeneity (MD= 31	
0.02, 95% CI= -0.42 to 0.46, p=0.93;  Q-test p=0.80; I2=0% ). The mean ICU length of stay 32	
was shorter in the IP group (MD= 1.09, 95% CI= 0.41 to 1.78, p=0.002).8-10 Heterogeneity 33	
was low ( Q-test: p=0.25, I2= 28%) (Figure 2b and 2c). 34	
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Two papers including 499 patients reported the mean monitoring duration for both groups.8, 10 1	
This did not differ when the results were pooled (MD= 1.78, 95% CI= -1.55 to 5.11, p=0.29). 2	
there was large statistical heterogeneity (Q-test: p <0.00001, I2=96%) (Figure 3e). 3	
Three studies including 607 patients reported device failures8, 10, 11 and there was no 4	
difference between the two groups in this respect (RR=0.98, 95% CI= 0.35 to 2.69, p=0.96). 5	
There was a low level of statistical heterogeneity (Q-test p=0.13, I2= 52%) (Figure 3d). 6	
Six reports including 3968 patients reported overall complications.2, 8-12 Five reports including 7	
1406 patients reported infections of the device, hemorrhage and ‘all complications’.2, 8, 10-12 8	
With regard to all complications, the VD group fared worse than the IP monitor group 9	
(RR=2.56, 95% CI=1.17 to 5.61, p= 0.02). Statistical heterogeneity was high (Q-test p< 10	
0.00001, I2=91%) (Figure 3a). Regarding infections2, 8, 10-12 in particular, such as meningitis 11	
and ventriculitis, VD patients were more at risk (RR=7.09, 95% CI= 2.64 to 19.04, p=0.0001), 12	
without evidence of statistical heterogeneity (Q-test p=0.59, I2= 0%) (Figure 3b). The VD 13	
group was also more at risk for hemorrhage (RR=2.64, 95% CI= 1.05 to 6.63, p=0.04),2, 8, 10-12 14	
without evidence of statistical heterogeneity (Q-test , p=0.94, I2= 0%) (Figure 3c).  15	
Episodes of RICH were only reported by one paper8, and thus did not lend themselves to a 16	
pooled analysis. The RR was 0.41, with a 95% CI ranging from 0.24 to 0.70.  17	
Risk of bias 18	
The overall quality of the studies is poor (Appendix 4), with one underpowered RCT (N=122) 19	
with high risk of bias with regard to blinding of trial personnel and of the outcome assessors. 20	
Of the 5 observational studies, 2 were judged as serious risk of bias and the other 3 were 21	
deemed at critical risk of bias according to the methodological assessment. 22	
The risk of bias for the RCT was low on most domains, except blinding of study personnel, 23	
which is inherently impossible given the nature of the intervention and the blinding of 24	
clinicians to the intervention in the clinical phase. The retrospective observational cohorts 25	
were judged as having overall serious9 and critical risk of bias respectively.2, 10, 11 26	
The criterion blinding could not be rated in the Cochrane tool since the monitoring device is 27	
identifiable when placed. 28	
Discussion 29	
This is the first systematic review that describes the potential effects of VDs versus IP 30	
monitor-guided management on patient outcomes. We found no difference in terms of 31	
mortality or functional outcome between the two groups. IP monitors are associated with a 32	
shorter ICU stay but not hospital stay and are associated with less complications, in particular 33	
less infections. The risk of malfunction is comparable among devices. However, strong 34	
inferences on effectiveness of VDs versus IP monitors cannot be made from this analyses 35	
given the high risk of bias of the included studies. 36	
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The effect of ICP monitoring is the subject of an ongoing debate in the scientific literature.1, 1	
13-15 General consensus remains that ICP monitoring is recommended in patients with severe 2	
TBI who have traumatic abnormalities on the CT scan.16  3	
Considerable practice variation exists with respect to the choice of monitoring device. A 4	
recent questionnaire-based study carried out by our group in 66 centers in Europe16 showed 5	
that both parenchymal and ventricular monitoring devices were available in more than half of 6	
centers (59%). One-third of the participants indicated that they used only parenchymal 7	
monitors, whereas one-tenth of the participants indicated that they used only ventricular 8	
catheters.16 9	
This variation noticed in the study carried out by our group can be explained in light of the 10	
limited evidence base for clinical practice. When looking at studies that provide the best 11	
quality evidence with a least risk of bias, the only RCT on the topic suggests the superiority of 12	
monitoring and treatment using VDs8 for both mortality and functional outcome, potentially 13	
also through a decrease in the number of patients requiring surgical decompression. Our meta-14	
analysis shows no difference between the two groups which likely arises from the pooling of 15	
results with lower quality studies. Despite the importance of ICP monitoring and the clinical 16	
relevance of the comparison between VDs and IP monitors, we only found 6 papers dealing 17	
with this head-to-head comparison. This is perhaps due to the idea that a monitoring device in 18	
itself cannot improve outcomes, but guide treatment and because certain imaging 19	
characteristics (midline shift, mass lesions, narrow ventricles) might deter clinicians from 20	
inserting VD, making RCTs difficult to carry out and less generalizable.  21	
It is essential to distinguish acute craniotomy for the evacuation of life-threatening space-22	
occupying lesions from decompressive craniectomy, a rescue therapy to resolve intracranial 23	
hypertension refractory to medical treatment because of the vastly different prognosis.  24	
This was, however, only properly defined as such in the paper by Liu and colleagues.8 In the 25	
other two papers that report this outcome9, 10, it is unclear whether patients received a 26	
decompressive craniectomy or a craniotomy with decompression of the lesion. Kasotakis et al 27	
report “surgical decompression” and do not define it10, whereas Aiolfi et al  report in the text 28	
“The need for craniectomy” and “Craniotomy/Craniectomy performed within 24 hours” in the 29	
table.9 When the results of Liu et al and Kasotakis et al were pooled, the difference was 30	
significant in that the VD group required surgical decompression more often. When the 31	
results of the Aiolfi study were added, the difference was no longer significant. Given the 32	
major differences in prognosis between a craniotomy with evacuation of a lesion and a 33	
craniectomy on patient outcomes, it is likely that confounding was introduced by adding the 34	
Aiolfi study to the pooled results, owing in part to the large number of patients included.9 35	
The overall complication rate and in particular to the risk of infection and haemorrhage were 36	
higher for patients receiving a VD when compared to those receiving an IP monitor.  37	
The infection risk for an VD in the literature ranges between as low as 0%17 and as high as 38	
22%17, and this needs to be addressed when VDs are used by the implementation of a strict 39	
protocol of insertion, care and maintenance. In this review the calculated infection rate and 40	
overall complication rates were higher in the VD groups, ranging from 2%8 to 9%12.  The IP 41	
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monitor group had consistently very low prevalence of infection, usually under 1%.2, 10  It is 1	
known that a longer duration of monitoring usually leads to a higher infection rate.12 Only two 2	
papers report the mean duration of monitoring and the pooled results show no statistically 3	
significant difference between the two groups,8, 10 but future research on this topic needs to 4	
address this potential confounder.  5	
Despite the difference being non-significant in all of the individual studies, the aggregated 6	
results show a significantly shorter duration of ICU admission in patients receiving IP 7	
monitors. At first glance, it might appear that the lower complication rate leads to a shorter 8	
ICU LOS. On average, patients spent one extra day in the ICU. Severe complications would 9	
prolong ICU stay for longer than a day and the hospital LOS does not differ significantly. 10	
This might, however, be a case of confounding by indication: the insertion of a ventricular 11	
probe requires a patent ventricle, and is best accomplished when the ventricular system is not 12	
displaced. In case of raised ICP the ventricles become slit and a considerable midline shift 13	
may develop, making the surgical insertion of the probe difficult or impossible. There is the 14	
risk, therefore, that VDs are used in less severe cases, where its insertion is feasible.  15	
When looking at variables collected in the 6 included papers, we strikingly found no mention 16	
of the effect of CSF drainage on therapy intensity level, save for the need for performing a 17	
surgical decompression and the ICU LOS and number of episodes of RICH as indications of 18	
therapy intensity (the latter only available in the RCT). We feel that this is a necessary 19	
addition for future studies, as the beneficial effect of controlling ICP through CSF drainage 20	
might be counteracted by the risk of adverse events. It is more likely to assume that VD use 21	
decreases treatment intensity and is in this respect beneficial than to assume that it has, as a 22	
standalone entity, a direct effect on patient outcomes.  23	
Moreover, except for the only RCT on the topic by Liu and colleagues8, no other papers 24	
report whether CSF was drained intermittently or continuously. Within the aforementioned 25	
trial CSF was drained intermittently. So far only small studies suggest a potential benefit of 26	
continuous drainage above intermittent.18 In addition, there was also no information available 27	
of crossover patients, i.e. patients that received an VD after receiving an IP monitor and 28	
whether there were differences in the readings. This also suggests another possible 29	
confounder: the values indicated by VDs during drainage might provide inaccurately low 30	
values, not detecting values above the threshold and leading to under-treatment.19 31	
Furthermore, no mention was made in any of the papers whether antibiotic impregnated 32	
catheters were used. These issues need to be dealt with when further research on this topic 33	
will be carried out. 34	
In light of the complications, the use of VDs might seem counterintuitive. However, in the 35	
pediatric population continuous CSF drainage is a relatively common practice with evidence 36	
to support improvements in both ICP management and injury biomarkers.20 In the adult 37	
population, however, only small studies show a potential benefit of continuous drainage18. 38	
This statement also figures as a recommendation in the guidelines.1  39	
In light of many unanswered questions, a large comparative effectiveness study,21 such as the 40	
ongoing CENTER-TBI and TRACK-TBI cohorts would be needed to address all of the 41	
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questions regarding the effectiveness, complication rate, and to assess the cost-effectiveness 1	
of each device while keeping the risk of bias moderate or low and work around the 2	
confounding. The topic of intermittent or continuous drainage also needs to be addressed in a 3	
larger dedicated trial, and the focus should also be on the effect of CSF drainage on treatment 4	
intensity.   5	
Despite the fact that the only RCT on this topic shows better results for patient outcomes, it 6	
did not create a paradigm shift in practice, nor does it figure in the current edition of the 7	
guidelines1. When all available data was pooled, the results of this RCT are challenged. 8	
Further high-quality comparisons are needed to address this issue.  9	
Deviations from the protocol and limitations 10	
We were unable to access absolute values of the GOS(E) in order to dichotomize. The only 11	
data available was the mean GOS for the two groups which is a limitation of this study. We 12	
would have favored an ordinal approach to data analysis.  13	
We also did not measure the relative risk of receiving an VD when one had received an IP 14	
monitor first. We included some studies that did not respect our 85% severe TBI rule, but 15	
given that we felt that the risk of infections when these devices are used in other injury types 16	
or in mixed injury types are comparable, we avoided the introduction of confounding of our 17	
results. VDs used in stroke are usually inserted in cases of intraventricular haemorrhage and 18	
kept in until the blood clears, which might lead to a longer monitoring duration in the VD 19	
group and consequently more infections. The pooled data available did not suggest a longer 20	
monitoring duration with VDs, but only 2 of the 6 papers reported this outcome.  21	
Subgroup analyses were impossible since the studies did not present the required data. Funnel 22	
plots could also not be compiled as there were insufficient studies in order to do so.  23	
 24	
Conclusion 25	
This systematic review suggests that in patients with severe or moderate TBI the use of VDs 26	
instead of IP monitors was not associated with less mortality or better functional outcome, but 27	
the patients did suffer more complications. Overall, these results need to be interpreted with 28	
caution given that the overall body of evidence is poor, consisting of mostly observational 29	
studies with serious and critical risk of bias. There remains a need for high quality head-to-30	
head comparisons of VDs and IP monitors. 31	
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